Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma
Xuqing Shen, Ningning Niu, Jing Xue
Abstract
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an extremely high lethality rate. Oncogenic KRAS activation has been proven to be a key driver of PDAC initiation and progression. There is increasing evidence that PDAC cells undergo extensive metabolic reprogramming to adapt to their extreme energy and biomass demands. Cell-intrinsic factors, such as KRAS mutations, are able to trigger metabolic rewriting. Here, we update recent advances in KRAS-driven metabolic reprogramming and the associated metabolic therapeutic potential in PDAC.
Topics & Concepts
KRASCancer researchReprogrammingMedicinePancreatic ductal adenocarcinomaMetabolic adaptationPancreatic cancerAdenocarcinomaInternal medicineCancerCellBiologyMetabolismGeneticsColorectal cancerPancreatic function and diabetesPancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism